effect of amiloride-h in central serous chorioretinopathy

Evaluation of the effectiveness of amiloride-H for treatment of patients suffer from central serous chorioretinopathy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190311043009N1

Enrollment

Registered

2019-05-09

Start date

2019-04-04

Completion date

Unknown

Last updated

2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central serous chorioretinopathy. Central serous chorioretinopathy, unspecified eye

Interventions

Intervention 1: Intervention group: This group will be treated with Amiloride-h that is combination of Amiloride and Hydrochlorothiazide . This drug exists as 5mg tablet that use one time in day for 3

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Presence of acute central serous chorioretinopathy less than past month

Exclusion criteria

Exclusion criteria: presence of ophthalmologic pathology same as glaucoma, retinal disease and uveitis use of previuos treatment, like as medical, PDT, laser photocoagulation

Design outcomes

Primary

Measure	Time frame
Best corrected visual acuity based on snellen chart. Timepoint: Measurement of best corrected visual acuity of the patient at first and 1, 3 month after begining treatment. Method of measurement: Snellen chart board.	—

Secondary

Measure	Time frame
Central macular thickness. Timepoint: At first and 1, 3 months after treatment. Method of measurement: Imaging of the retina with use of optical coherence tomography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad hossein Taghdiri

Esfahan University of Medical Sciences

dr.taghdiri@resident.mui.ac.ir+98 31 3447 6011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026